The CPMP considered that the restricted indication (i. e. “ symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy”) more closely mirrors the current clinical recommendations on the management of COPD (e. g.